Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

Terminated

3

Start Date 04/01/2008

Age of Trial (yrs) 16.7

First-line

KIT/PDGFRA inhibitor+ VEGF inhibitor (antibody)

Block KIT Block tumor blood vessel growth

Specifically GIST and only GIST

CDR0000482236, U10CA032102, S0502, CALGB-S0502, CAN-NCIC-S0502

NCI, CALGB, NCIC, SWOG

See each trial site.

Randomized

Oral IV

NOTE:
This trial is no longer recruiting patients.
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving imatinib mesylate together with bevacizumab may kill more tumor cells. It is not yet known whether imatinib mesylate and bevacizumab are more effective than imatinib mesylate alone in treating gastrointestinal stromal tumor.

PURPOSE: This randomized phase III trial is studying imatinib mesylate and bevacizumab to see how well they work compared to imatinib mesylate alone in treating patients with metastatic or unresectable gastrointestinal stromal tumor.